Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAX-40279 + KN046 in Advanced Solid Tumors
NCT05425602Phase 2Unknown
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of nefextinib in solid tumor (advanced stage), gastric cancer (GC), small cell lung cancer (SCLC), sponsored by Guangzhou Zaiji Medical Technology. Status: unknown.
02
Drugs
nefextinib
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05425602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05425602.